YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
Rhea-AI Summary
YD Bio Limited (NASDAQ:YDES) reported its H1 2025 financial results, marked by strategic developments despite financial headwinds. The company's net revenue decreased 9% to $204,007, while operating expenses increased significantly to $2.0 million, resulting in a net loss of $1.9 million.
Key developments include securing $13.2 million in PIPE financing through a business combination with Breeze Holdings, advancing DNA methylation-based cancer detection technology, and expanding into ophthalmologic innovations. The company launched a pancreatic cancer screening LDT and plans to introduce a breast cancer recurrence monitoring LDT. Additionally, YD Bio is developing corneal stem-cell and exosome-based treatments for various eye conditions, with clinical trials planned for 2027.
Positive
- Secured $13.2 million in gross proceeds through PIPE financing
- Successfully completed business combination with Breeze Holdings to become publicly traded
- Launched DNA methylation-based pancreatic cancer screening LDT
- Obtained exclusive licensing for breast cancer detection across U.S., Europe, and Asia
- Maintained stable gross profit at $69,000 despite revenue decline
Negative
- Net revenue declined 9% to $204,007
- Net loss increased significantly to $1.9 million from $0.17 million year-over-year
- Operating expenses surged to $2.0 million from $262,264
- Cash and cash equivalents decreased to $469,520 from $3,132,298
- Clinical trials for key ophthalmologic treatments not starting until 2027
News Market Reaction
On the day this news was published, YDES gained 7.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.2% during that session. Argus tracked a trough of -10.5% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $101M to the company's valuation, bringing the market cap to $1.39B at that time.
Data tracked by StockTitan Argus on the day of publication.
TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its unaudited financial results for the six months ended June 30, 2025.
Management Commentary
“With the closing of our business combination with Breeze Holdings Acquisition Corp. (“Breeze Holdings’) in August and the concurrent closing of a private investment in public equity financing, securing
“Despite a slight decrease in net revenue, we managed to continue investing in general and administrative functions and R&D to expand capacity. We also advanced two licensed patents to execute growth strategy during the reporting period.”
“Our vision remains to deliver minimally invasive, early cancer detection globally and pioneer regenerative ophthalmology therapies. As previously announced, through exclusive licensing with EG BioMed Co., Ltd. (“EG BioMed”), we’ve launched a DNA methylation-based pancreatic cancer screening LDT and will introduce a breast cancer recurrence monitoring LDT later this year. In partnership with 3D Global Biotech Inc. (“3D Global”), we are preparing corneal stem-cell and exosome-based treatments for dry eye, glaucoma and corneal injury, with clinical trials slated for 2027. Simultaneously, our proven track record as a supplier of investigational drugs and ancillary materials underpins a robust clinical-trial services business.”
“We believe YD Bio Limited is positioned to capture a share of the multibillion-dollar oncology diagnostics, ocular therapeutics and clinical-trial services markets. Our strengthened balance sheet, public-market profile and diversified pipeline set the stage for sustainable revenue growth, margin expansion and long-term value creation for patients, partners and shareholders,” Dr. Shen said.
YD Biopharma’s Half Year 2025 Financial Results
YD Biopharma’s vision is to deliver early cancer detection globally, offering patients additional less invasive treatment options. It will focus on product development, equipment upgrades, and capacity expansion to meet customer quality and volume standards. YD Biopharma plans to achieve this through new products, acquisitions, licensing, proprietary medical-industry IP, and investments in global manufacturing processes. YD Biopharma will also grow its IP portfolio’s value to support worldwide product licensure.
Net Revenue
Net revenue fell by
Top five individual products by revenue for the six months ended June 30, 2025:
| Keytruda injection (Drugs) | $ | 42,503 | ||
| Exolens Hioxifilcon (Contact lenses) | 35,000 | |||
| Pharmorubicin Injection (Drugs) | 17,938 | |||
| 12-Lead Electrocardiograph (Medical and related products) | 10,048 | |||
| Solu-Medrol Injection (Drugs) | 8,478 | |||
| Subtotal | $ | 113,967 |
Top five individual products by revenue for the six months ended June 30, 2024:
| PVA Eye Cleansing Wipes (Medical and related products) | $ | 49,077 | ||
| Keytruda injection (Drugs) | 24,837 | |||
| Fluorescence Cell Counter and Viability Analyzer (Medical and related products) | 23,326 | |||
| Giotrif Film-Coated Tablets (Medical and related products) | 14,915 | |||
| Faslodex Solution for injection (Drugs) | 14,175 | |||
| Subtotal | $ | 128,330 |
Cost of Revenue
Cost of revenue declined by
Gross Profit
Gross profit was unchanged at
● improving resale product and raw material sources;
● increasing and diversifying our customer base;
● introducing new product lines and subcontractors with higher margins;
● commencing new cancer early detection services;
● establishing additional licensing agreements;
● reducing component costs through greater purchasing power and scalability; and
● expanding strategic relationships with component providers.
Operating Expenses
Operating expenses totaled
Net Loss
YD Biopharma has operated primarily as a development stage company since its formation. Net loss was
Cash and Cash Equivalents
Cash and cash equivalents including unrestricted cash with maturities of three months or less stood at
Major Developments
YD Biopharma advanced ocular therapies via a 3D Global license for corneal mesenchymal stem cells and exosomes, supporting an IRB-approved corneal specimen study at Shuang-Ho Hospital. In 2025, It initiated clinical trial applications for exosome-based contact lenses and artificial tears for dry eye.
YD Biopharma is also expanding into oncology diagnostics through EG BioMed. In June 2024, it secured patents, technology, and U.S. market authorization for high-accuracy pancreatic cancer methylation detection, with plans for a U.S. independent lab and healthcare partnerships. On September 30, 2024, it signed an exclusive license for breast cancer detection across the U.S., Europe, and Asia, with a
About YD Bio Limited
YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com
FAQ
What were YD Bio's (YDES) key financial results for H1 2025?
How much funding did YD Bio (YDES) secure in its PIPE financing?
What are YD Bio's (YDES) main product developments in cancer detection?
What is YD Bio's (YDES) timeline for ophthalmologic clinical trials?
What were YD Bio's (YDES) top revenue-generating products in H1 2025?
